Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

H1N1 Vaccination Market

ID: MRFR/HC/38945-HCR
100 Pages
Rahul Gotadki
Last Updated: April 24, 2026

H1N1 Vaccination Market Research Report: Size, Share, Trend Analysis By Vaccine Strain (Monovalent, Trivalent, Quadrivalent), By Patient Age Group (Pediatric (18 years), Adult (18 years), By Dosage Form (Injectable, Nasal Spray), By Distribution Channel (Hospitals Clinics, Pharmacies, Online Retailers) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

H1N1 Vaccination Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Vaccine Strain (USD Billion)
  49.     4.1.1 Monovalent
  50.     4.1.2 Trivalent
  51.     4.1.3 Quadrivalent
  52.   4.2 Healthcare, BY Patient Age Group (USD Billion)
  53.     4.2.1 Pediatric (18 years)
  54.     4.2.2 Adult (18 years)
  55.   4.3 Healthcare, BY Dosage Form (USD Billion)
  56.     4.3.1 Injectable
  57.     4.3.2 Nasal Spray
  58.   4.4 Healthcare, BY Distribution Channel (USD Billion)
  59.     4.4.1 Hospitals Clinics
  60.     4.4.2 Pharmacies
  61.     4.4.3 Online Retailers
  62.   4.5 Healthcare, BY Region (USD Billion)
  63.     4.5.1 North America
  64.       4.5.1.1 US
  65.       4.5.1.2 Canada
  66.     4.5.2 Europe
  67.       4.5.2.1 Germany
  68.       4.5.2.2 UK
  69.       4.5.2.3 France
  70.       4.5.2.4 Russia
  71.       4.5.2.5 Italy
  72.       4.5.2.6 Spain
  73.       4.5.2.7 Rest of Europe
  74.     4.5.3 APAC
  75.       4.5.3.1 China
  76.       4.5.3.2 India
  77.       4.5.3.3 Japan
  78.       4.5.3.4 South Korea
  79.       4.5.3.5 Malaysia
  80.       4.5.3.6 Thailand
  81.       4.5.3.7 Indonesia
  82.       4.5.3.8 Rest of APAC
  83.     4.5.4 South America
  84.       4.5.4.1 Brazil
  85.       4.5.4.2 Mexico
  86.       4.5.4.3 Argentina
  87.       4.5.4.4 Rest of South America
  88.     4.5.5 MEA
  89.       4.5.5.1 GCC Countries
  90.       4.5.5.2 South Africa
  91.       4.5.5.3 Rest of MEA
  92. 5 SECTION V: COMPETITIVE ANALYSIS
  93.   5.1 Competitive Landscape
  94.     5.1.1 Overview
  95.     5.1.2 Competitive Analysis
  96.     5.1.3 Market share Analysis
  97.     5.1.4 Major Growth Strategy in the Healthcare
  98.     5.1.5 Competitive Benchmarking
  99.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  100.     5.1.7 Key developments and growth strategies
  101.       5.1.7.1 New Product Launch/Service Deployment
  102.       5.1.7.2 Merger & Acquisitions
  103.       5.1.7.3 Joint Ventures
  104.     5.1.8 Major Players Financial Matrix
  105.       5.1.8.1 Sales and Operating Income
  106.       5.1.8.2 Major Players R&D Expenditure. 2023
  107.   5.2 Company Profiles
  108.     5.2.1 Sanofi (FR)
  109.       5.2.1.1 Financial Overview
  110.       5.2.1.2 Products Offered
  111.       5.2.1.3 Key Developments
  112.       5.2.1.4 SWOT Analysis
  113.       5.2.1.5 Key Strategies
  114.     5.2.2 GlaxoSmithKline (GB)
  115.       5.2.2.1 Financial Overview
  116.       5.2.2.2 Products Offered
  117.       5.2.2.3 Key Developments
  118.       5.2.2.4 SWOT Analysis
  119.       5.2.2.5 Key Strategies
  120.     5.2.3 Pfizer (US)
  121.       5.2.3.1 Financial Overview
  122.       5.2.3.2 Products Offered
  123.       5.2.3.3 Key Developments
  124.       5.2.3.4 SWOT Analysis
  125.       5.2.3.5 Key Strategies
  126.     5.2.4 Novartis (CH)
  127.       5.2.4.1 Financial Overview
  128.       5.2.4.2 Products Offered
  129.       5.2.4.3 Key Developments
  130.       5.2.4.4 SWOT Analysis
  131.       5.2.4.5 Key Strategies
  132.     5.2.5 Merck & Co. (US)
  133.       5.2.5.1 Financial Overview
  134.       5.2.5.2 Products Offered
  135.       5.2.5.3 Key Developments
  136.       5.2.5.4 SWOT Analysis
  137.       5.2.5.5 Key Strategies
  138.     5.2.6 Baxter International (US)
  139.       5.2.6.1 Financial Overview
  140.       5.2.6.2 Products Offered
  141.       5.2.6.3 Key Developments
  142.       5.2.6.4 SWOT Analysis
  143.       5.2.6.5 Key Strategies
  144.     5.2.7 AstraZeneca (GB)
  145.       5.2.7.1 Financial Overview
  146.       5.2.7.2 Products Offered
  147.       5.2.7.3 Key Developments
  148.       5.2.7.4 SWOT Analysis
  149.       5.2.7.5 Key Strategies
  150.     5.2.8 CSL Limited (AU)
  151.       5.2.8.1 Financial Overview
  152.       5.2.8.2 Products Offered
  153.       5.2.8.3 Key Developments
  154.       5.2.8.4 SWOT Analysis
  155.       5.2.8.5 Key Strategies
  156.   5.3 Appendix
  157.     5.3.1 References
  158.     5.3.2 Related Reports
  159. 6 LIST OF FIGURES
  160.   6.1 MARKET SYNOPSIS
  161.   6.2 NORTH AMERICA MARKET ANALYSIS
  162.   6.3 US MARKET ANALYSIS BY VACCINE STRAIN
  163.   6.4 US MARKET ANALYSIS BY PATIENT AGE GROUP
  164.   6.5 US MARKET ANALYSIS BY DOSAGE FORM
  165.   6.6 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  166.   6.7 CANADA MARKET ANALYSIS BY VACCINE STRAIN
  167.   6.8 CANADA MARKET ANALYSIS BY PATIENT AGE GROUP
  168.   6.9 CANADA MARKET ANALYSIS BY DOSAGE FORM
  169.   6.10 CANADA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  170.   6.11 EUROPE MARKET ANALYSIS
  171.   6.12 GERMANY MARKET ANALYSIS BY VACCINE STRAIN
  172.   6.13 GERMANY MARKET ANALYSIS BY PATIENT AGE GROUP
  173.   6.14 GERMANY MARKET ANALYSIS BY DOSAGE FORM
  174.   6.15 GERMANY MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  175.   6.16 UK MARKET ANALYSIS BY VACCINE STRAIN
  176.   6.17 UK MARKET ANALYSIS BY PATIENT AGE GROUP
  177.   6.18 UK MARKET ANALYSIS BY DOSAGE FORM
  178.   6.19 UK MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  179.   6.20 FRANCE MARKET ANALYSIS BY VACCINE STRAIN
  180.   6.21 FRANCE MARKET ANALYSIS BY PATIENT AGE GROUP
  181.   6.22 FRANCE MARKET ANALYSIS BY DOSAGE FORM
  182.   6.23 FRANCE MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  183.   6.24 RUSSIA MARKET ANALYSIS BY VACCINE STRAIN
  184.   6.25 RUSSIA MARKET ANALYSIS BY PATIENT AGE GROUP
  185.   6.26 RUSSIA MARKET ANALYSIS BY DOSAGE FORM
  186.   6.27 RUSSIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  187.   6.28 ITALY MARKET ANALYSIS BY VACCINE STRAIN
  188.   6.29 ITALY MARKET ANALYSIS BY PATIENT AGE GROUP
  189.   6.30 ITALY MARKET ANALYSIS BY DOSAGE FORM
  190.   6.31 ITALY MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  191.   6.32 SPAIN MARKET ANALYSIS BY VACCINE STRAIN
  192.   6.33 SPAIN MARKET ANALYSIS BY PATIENT AGE GROUP
  193.   6.34 SPAIN MARKET ANALYSIS BY DOSAGE FORM
  194.   6.35 SPAIN MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  195.   6.36 REST OF EUROPE MARKET ANALYSIS BY VACCINE STRAIN
  196.   6.37 REST OF EUROPE MARKET ANALYSIS BY PATIENT AGE GROUP
  197.   6.38 REST OF EUROPE MARKET ANALYSIS BY DOSAGE FORM
  198.   6.39 REST OF EUROPE MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  199.   6.40 APAC MARKET ANALYSIS
  200.   6.41 CHINA MARKET ANALYSIS BY VACCINE STRAIN
  201.   6.42 CHINA MARKET ANALYSIS BY PATIENT AGE GROUP
  202.   6.43 CHINA MARKET ANALYSIS BY DOSAGE FORM
  203.   6.44 CHINA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  204.   6.45 INDIA MARKET ANALYSIS BY VACCINE STRAIN
  205.   6.46 INDIA MARKET ANALYSIS BY PATIENT AGE GROUP
  206.   6.47 INDIA MARKET ANALYSIS BY DOSAGE FORM
  207.   6.48 INDIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  208.   6.49 JAPAN MARKET ANALYSIS BY VACCINE STRAIN
  209.   6.50 JAPAN MARKET ANALYSIS BY PATIENT AGE GROUP
  210.   6.51 JAPAN MARKET ANALYSIS BY DOSAGE FORM
  211.   6.52 JAPAN MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  212.   6.53 SOUTH KOREA MARKET ANALYSIS BY VACCINE STRAIN
  213.   6.54 SOUTH KOREA MARKET ANALYSIS BY PATIENT AGE GROUP
  214.   6.55 SOUTH KOREA MARKET ANALYSIS BY DOSAGE FORM
  215.   6.56 SOUTH KOREA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  216.   6.57 MALAYSIA MARKET ANALYSIS BY VACCINE STRAIN
  217.   6.58 MALAYSIA MARKET ANALYSIS BY PATIENT AGE GROUP
  218.   6.59 MALAYSIA MARKET ANALYSIS BY DOSAGE FORM
  219.   6.60 MALAYSIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  220.   6.61 THAILAND MARKET ANALYSIS BY VACCINE STRAIN
  221.   6.62 THAILAND MARKET ANALYSIS BY PATIENT AGE GROUP
  222.   6.63 THAILAND MARKET ANALYSIS BY DOSAGE FORM
  223.   6.64 THAILAND MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  224.   6.65 INDONESIA MARKET ANALYSIS BY VACCINE STRAIN
  225.   6.66 INDONESIA MARKET ANALYSIS BY PATIENT AGE GROUP
  226.   6.67 INDONESIA MARKET ANALYSIS BY DOSAGE FORM
  227.   6.68 INDONESIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  228.   6.69 REST OF APAC MARKET ANALYSIS BY VACCINE STRAIN
  229.   6.70 REST OF APAC MARKET ANALYSIS BY PATIENT AGE GROUP
  230.   6.71 REST OF APAC MARKET ANALYSIS BY DOSAGE FORM
  231.   6.72 REST OF APAC MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  232.   6.73 SOUTH AMERICA MARKET ANALYSIS
  233.   6.74 BRAZIL MARKET ANALYSIS BY VACCINE STRAIN
  234.   6.75 BRAZIL MARKET ANALYSIS BY PATIENT AGE GROUP
  235.   6.76 BRAZIL MARKET ANALYSIS BY DOSAGE FORM
  236.   6.77 BRAZIL MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  237.   6.78 MEXICO MARKET ANALYSIS BY VACCINE STRAIN
  238.   6.79 MEXICO MARKET ANALYSIS BY PATIENT AGE GROUP
  239.   6.80 MEXICO MARKET ANALYSIS BY DOSAGE FORM
  240.   6.81 MEXICO MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  241.   6.82 ARGENTINA MARKET ANALYSIS BY VACCINE STRAIN
  242.   6.83 ARGENTINA MARKET ANALYSIS BY PATIENT AGE GROUP
  243.   6.84 ARGENTINA MARKET ANALYSIS BY DOSAGE FORM
  244.   6.85 ARGENTINA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  245.   6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY VACCINE STRAIN
  246.   6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATIENT AGE GROUP
  247.   6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY DOSAGE FORM
  248.   6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  249.   6.90 MEA MARKET ANALYSIS
  250.   6.91 GCC COUNTRIES MARKET ANALYSIS BY VACCINE STRAIN
  251.   6.92 GCC COUNTRIES MARKET ANALYSIS BY PATIENT AGE GROUP
  252.   6.93 GCC COUNTRIES MARKET ANALYSIS BY DOSAGE FORM
  253.   6.94 GCC COUNTRIES MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  254.   6.95 SOUTH AFRICA MARKET ANALYSIS BY VACCINE STRAIN
  255.   6.96 SOUTH AFRICA MARKET ANALYSIS BY PATIENT AGE GROUP
  256.   6.97 SOUTH AFRICA MARKET ANALYSIS BY DOSAGE FORM
  257.   6.98 SOUTH AFRICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  258.   6.99 REST OF MEA MARKET ANALYSIS BY VACCINE STRAIN
  259.   6.100 REST OF MEA MARKET ANALYSIS BY PATIENT AGE GROUP
  260.   6.101 REST OF MEA MARKET ANALYSIS BY DOSAGE FORM
  261.   6.102 REST OF MEA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  262.   6.103 KEY BUYING CRITERIA OF HEALTHCARE
  263.   6.104 RESEARCH PROCESS OF MRFR
  264.   6.105 DRO ANALYSIS OF HEALTHCARE
  265.   6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  266.   6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  267.   6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
  268.   6.109 HEALTHCARE, BY VACCINE STRAIN, 2024 (% SHARE)
  269.   6.110 HEALTHCARE, BY VACCINE STRAIN, 2024 TO 2035 (USD Billion)
  270.   6.111 HEALTHCARE, BY PATIENT AGE GROUP, 2024 (% SHARE)
  271.   6.112 HEALTHCARE, BY PATIENT AGE GROUP, 2024 TO 2035 (USD Billion)
  272.   6.113 HEALTHCARE, BY DOSAGE FORM, 2024 (% SHARE)
  273.   6.114 HEALTHCARE, BY DOSAGE FORM, 2024 TO 2035 (USD Billion)
  274.   6.115 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
  275.   6.116 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Billion)
  276.   6.117 BENCHMARKING OF MAJOR COMPETITORS
  277. 7 LIST OF TABLES
  278.   7.1 LIST OF ASSUMPTIONS
  279.     7.1.1
  280.   7.2 North America MARKET SIZE ESTIMATES; FORECAST
  281.     7.2.1 BY VACCINE STRAIN, 2025-2035 (USD Billion)
  282.     7.2.2 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  283.     7.2.3 BY DOSAGE FORM, 2025-2035 (USD Billion)
  284.     7.2.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  285.   7.3 US MARKET SIZE ESTIMATES; FORECAST
  286.     7.3.1 BY VACCINE STRAIN, 2025-2035 (USD Billion)
  287.     7.3.2 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  288.     7.3.3 BY DOSAGE FORM, 2025-2035 (USD Billion)
  289.     7.3.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  290.   7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  291.     7.4.1 BY VACCINE STRAIN, 2025-2035 (USD Billion)
  292.     7.4.2 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  293.     7.4.3 BY DOSAGE FORM, 2025-2035 (USD Billion)
  294.     7.4.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  295.   7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  296.     7.5.1 BY VACCINE STRAIN, 2025-2035 (USD Billion)
  297.     7.5.2 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  298.     7.5.3 BY DOSAGE FORM, 2025-2035 (USD Billion)
  299.     7.5.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  300.   7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  301.     7.6.1 BY VACCINE STRAIN, 2025-2035 (USD Billion)
  302.     7.6.2 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  303.     7.6.3 BY DOSAGE FORM, 2025-2035 (USD Billion)
  304.     7.6.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  305.   7.7 UK MARKET SIZE ESTIMATES; FORECAST
  306.     7.7.1 BY VACCINE STRAIN, 2025-2035 (USD Billion)
  307.     7.7.2 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  308.     7.7.3 BY DOSAGE FORM, 2025-2035 (USD Billion)
  309.     7.7.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  310.   7.8 France MARKET SIZE ESTIMATES; FORECAST
  311.     7.8.1 BY VACCINE STRAIN, 2025-2035 (USD Billion)
  312.     7.8.2 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  313.     7.8.3 BY DOSAGE FORM, 2025-2035 (USD Billion)
  314.     7.8.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  315.   7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  316.     7.9.1 BY VACCINE STRAIN, 2025-2035 (USD Billion)
  317.     7.9.2 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  318.     7.9.3 BY DOSAGE FORM, 2025-2035 (USD Billion)
  319.     7.9.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  320.   7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  321.     7.10.1 BY VACCINE STRAIN, 2025-2035 (USD Billion)
  322.     7.10.2 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  323.     7.10.3 BY DOSAGE FORM, 2025-2035 (USD Billion)
  324.     7.10.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  325.   7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  326.     7.11.1 BY VACCINE STRAIN, 2025-2035 (USD Billion)
  327.     7.11.2 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  328.     7.11.3 BY DOSAGE FORM, 2025-2035 (USD Billion)
  329.     7.11.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  330.   7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  331.     7.12.1 BY VACCINE STRAIN, 2025-2035 (USD Billion)
  332.     7.12.2 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  333.     7.12.3 BY DOSAGE FORM, 2025-2035 (USD Billion)
  334.     7.12.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  335.   7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  336.     7.13.1 BY VACCINE STRAIN, 2025-2035 (USD Billion)
  337.     7.13.2 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  338.     7.13.3 BY DOSAGE FORM, 2025-2035 (USD Billion)
  339.     7.13.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  340.   7.14 China MARKET SIZE ESTIMATES; FORECAST
  341.     7.14.1 BY VACCINE STRAIN, 2025-2035 (USD Billion)
  342.     7.14.2 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  343.     7.14.3 BY DOSAGE FORM, 2025-2035 (USD Billion)
  344.     7.14.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  345.   7.15 India MARKET SIZE ESTIMATES; FORECAST
  346.     7.15.1 BY VACCINE STRAIN, 2025-2035 (USD Billion)
  347.     7.15.2 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  348.     7.15.3 BY DOSAGE FORM, 2025-2035 (USD Billion)
  349.     7.15.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  350.   7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  351.     7.16.1 BY VACCINE STRAIN, 2025-2035 (USD Billion)
  352.     7.16.2 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  353.     7.16.3 BY DOSAGE FORM, 2025-2035 (USD Billion)
  354.     7.16.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  355.   7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  356.     7.17.1 BY VACCINE STRAIN, 2025-2035 (USD Billion)
  357.     7.17.2 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  358.     7.17.3 BY DOSAGE FORM, 2025-2035 (USD Billion)
  359.     7.17.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  360.   7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  361.     7.18.1 BY VACCINE STRAIN, 2025-2035 (USD Billion)
  362.     7.18.2 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  363.     7.18.3 BY DOSAGE FORM, 2025-2035 (USD Billion)
  364.     7.18.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  365.   7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  366.     7.19.1 BY VACCINE STRAIN, 2025-2035 (USD Billion)
  367.     7.19.2 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  368.     7.19.3 BY DOSAGE FORM, 2025-2035 (USD Billion)
  369.     7.19.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  370.   7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  371.     7.20.1 BY VACCINE STRAIN, 2025-2035 (USD Billion)
  372.     7.20.2 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  373.     7.20.3 BY DOSAGE FORM, 2025-2035 (USD Billion)
  374.     7.20.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  375.   7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  376.     7.21.1 BY VACCINE STRAIN, 2025-2035 (USD Billion)
  377.     7.21.2 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  378.     7.21.3 BY DOSAGE FORM, 2025-2035 (USD Billion)
  379.     7.21.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  380.   7.22 South America MARKET SIZE ESTIMATES; FORECAST
  381.     7.22.1 BY VACCINE STRAIN, 2025-2035 (USD Billion)
  382.     7.22.2 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  383.     7.22.3 BY DOSAGE FORM, 2025-2035 (USD Billion)
  384.     7.22.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  385.   7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  386.     7.23.1 BY VACCINE STRAIN, 2025-2035 (USD Billion)
  387.     7.23.2 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  388.     7.23.3 BY DOSAGE FORM, 2025-2035 (USD Billion)
  389.     7.23.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  390.   7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  391.     7.24.1 BY VACCINE STRAIN, 2025-2035 (USD Billion)
  392.     7.24.2 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  393.     7.24.3 BY DOSAGE FORM, 2025-2035 (USD Billion)
  394.     7.24.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  395.   7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  396.     7.25.1 BY VACCINE STRAIN, 2025-2035 (USD Billion)
  397.     7.25.2 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  398.     7.25.3 BY DOSAGE FORM, 2025-2035 (USD Billion)
  399.     7.25.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  400.   7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  401.     7.26.1 BY VACCINE STRAIN, 2025-2035 (USD Billion)
  402.     7.26.2 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  403.     7.26.3 BY DOSAGE FORM, 2025-2035 (USD Billion)
  404.     7.26.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  405.   7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  406.     7.27.1 BY VACCINE STRAIN, 2025-2035 (USD Billion)
  407.     7.27.2 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  408.     7.27.3 BY DOSAGE FORM, 2025-2035 (USD Billion)
  409.     7.27.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  410.   7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  411.     7.28.1 BY VACCINE STRAIN, 2025-2035 (USD Billion)
  412.     7.28.2 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  413.     7.28.3 BY DOSAGE FORM, 2025-2035 (USD Billion)
  414.     7.28.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  415.   7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  416.     7.29.1 BY VACCINE STRAIN, 2025-2035 (USD Billion)
  417.     7.29.2 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  418.     7.29.3 BY DOSAGE FORM, 2025-2035 (USD Billion)
  419.     7.29.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  420.   7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  421.     7.30.1 BY VACCINE STRAIN, 2025-2035 (USD Billion)
  422.     7.30.2 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  423.     7.30.3 BY DOSAGE FORM, 2025-2035 (USD Billion)
  424.     7.30.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  425.   7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  426.     7.31.1
  427.   7.32 ACQUISITION/PARTNERSHIP
  428.     7.32.1

Healthcare Market Segmentation

Healthcare By Vaccine Strain (USD Billion, 2025-2035)

  • Monovalent
  • Trivalent
  • Quadrivalent

Healthcare By Patient Age Group (USD Billion, 2025-2035)

  • Pediatric (18 years)
  • Adult (18 years)

Healthcare By Dosage Form (USD Billion, 2025-2035)

  • Injectable
  • Nasal Spray

Healthcare By Distribution Channel (USD Billion, 2025-2035)

  • Hospitals Clinics
  • Pharmacies
  • Online Retailers

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions